DENVER, May 12, 2011 /PRNewswire/ — Oncimmune®
LLC , maker of EarlyCDT™-Lung,
a simple blood test that aids physicians in the risk assessment and

early detection of lung cancer, today announced that four
poster presentations during the American Thoracic Society’s (ATS)
International Conference May 13 – 18 in Denver will collectively
highlight the diagnostic and economic benefits of EarlyCDT-Lung.
 Oncimmune’s EarlyCDT-Lung
test uses a panel of tumor antigens to detect the presence of
immuno-biomarkers produced in the form of autoantibodies by the
patient’s immune system.  Elevation of any one of the panel of
immuno-biomarkers (autoantibodies) above a predetermined cut-off
value suggests that a tumor might be present.  These studies
follow data presented at the American College of Chest Physicians
in fourth quarter of last year.

The studies presented at the ATS meeting validate that EarlyCDT-Lung
detects all types of lung cancers at all stages, including early
stage disease. Previous studies have shown that immuno-biomarkers
can be detected up to five years before tumors can be seen in
routine diagnostic imaging procedures such as CT.

Abstracts reporting EarlyCDT-Lung’s diagnostic and
economic benefits of immuno-biomarkers in early detection of solid
tumor lung cancers during the ATS meeting include:

• Cost-Effectiveness of Screening Older Adult Smokers for
  Lung Cancer with an Autoantibody Test (AABT), Abstract:
   21114, May 16, Poster viewing: 10:45 a.m. – 12:30 p.m.
• </

  ‘/>”/>

SOURCE